Pollack, C. V. Jr., Reilly, P. A., Eikelboom, J., et al.: Idarucizumab for dabigatran reversal. N. Engl. J. Med., 2015, 373 (6), 511–520. 12 Eikelboom, J. W
Glund, S., Stangier, J., Schmohl, M., et al.: Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised
of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab. Vasc. Health Risk Manag., 2016, 12, 35–44. 10 Pollack, C. V. Jr
anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018; 39: 1330–1393. 18 Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for
anticoagulants in patients with severe bleedings or urgent surgical procedures. The new dabigatran antidote: the place of idarucizumab in clinical practice. [Teendők súlyos vérzés vagy sürgős sebészeti